Results 321 to 330 of about 12,660,283 (403)
Autosomal Recessive Spastic Ataxia of Charlevoix‐Saguenay in Two Half‐Siblings
ABSTRACT Autosomal recessive spastic ataxia of Charlevoix‐Saguenay (ARSACS) is caused by biallelic pathogenic variants in the SACS gene. We report the clinical, radiologic and neurophysiologic features of a pair of half‐siblings who presented with progressive cerebellar ataxia, peripheral neuropathy and upper motor neuron signs.
Dennis Yeow +6 more
wiley +1 more source
Mumps Virus: Replication, Immune Response, and the Changing Landscape of Vaccine Effectiveness. [PDF]
Risalvato J.
europepmc +1 more source
Insights Into the Antigenic Repertoire of Unclassified Synaptic Antibodies
ABSTRACT Objective We sought to characterize the sixth most common finding in our neuroimmunological laboratory practice (tissue assay‐observed unclassified neural antibodies [UNAs]), combining protein microarray and phage immunoprecipitation sequencing (PhIP‐Seq). Methods Patient specimens (258; 133 serums; 125 CSF) meeting UNA criteria were profiled;
Michael Gilligan +22 more
wiley +1 more source
Editorial: Molecular mechanisms of the host immune response to <i>Toxoplasma gondii</i> infection. [PDF]
Yang J, Fang R.
europepmc +1 more source
Dietary Puerarin Supplementation Improves Immune Response and Antioxidant Capacity of Sows [PDF]
Shanchuan Cao +4 more
openalex +1 more source
Network Localization of Fatigue in Multiple Sclerosis
ABSTRACT Background Fatigue is among the most common symptoms and one of the main factors determining the quality of life in multiple sclerosis (MS). However, the neurobiological mechanisms underlying fatigue are not fully understood. Here we studied lesion locations and their connections in individuals with MS, aiming to identify brain networks ...
Olli Likitalo +12 more
wiley +1 more source
Immunohistochemical Characterization of the Immune Response in Chronic Endometritis Caused by <i>Chlamydia trachomatis</i>. [PDF]
Miranda-Maldonado I +6 more
europepmc +1 more source
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin +2 more
wiley +1 more source

